| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Stanniocalcin-1, STC-1, STC1, STC |
| Entrez GeneID | 6781 |
| WB Predicted band size | 27.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This STC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 193-221 amino acids from the C-terminal region of human STC1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于STC1抗体的3篇参考文献摘要(文献标题和作者为虚构，供参考)：
1. **《STC1单克隆抗体的制备及其在肿瘤检测中的应用》**
作者：李明等
摘要：研究通过重组人STC1蛋白免疫小鼠，成功制备了高特异性的STC1单克隆抗体。实验验证该抗体可用于ELISA和免疫组化检测，并在乳腺癌组织中检测到STC1的高表达，提示其作为肿瘤生物标志物的潜力。
2. **《STC1在糖尿病肾病中的表达调控及抗体干预研究》**
作者：Smith J, et al.
摘要：利用STC1抗体阻断实验发现，抑制STC1可减轻肾小管上皮细胞的氧化应激损伤，表明STC1在糖尿病肾病进展中起关键作用，为靶向治疗提供了新方向。
3. **《STC1抗体通过调节PI3K/AKT通路抑制肝癌细胞迁移》**
作者：王磊等
摘要：研究采用STC1中和抗体处理肝癌细胞，发现其能显著抑制细胞迁移和侵袭能力。机制研究表明，抗体通过下调PI3K/AKT信号通路发挥抗肿瘤效应。
注：以上内容为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词“STC1 antibody”或“Stanniocalcin-1 antibody”获取。
The STC1 antibody targets stanniocalcin-1 (STC1), a glycoprotein hormone initially identified in fish for its role in calcium and phosphate homeostasis. In mammals, STC1 is widely expressed in tissues such as the kidneys, ovaries, and prostate, and is implicated in diverse physiological processes, including cellular stress responses, apoptosis regulation, and ion transport. Its overexpression has been observed in various cancers (e.g., breast, lung, and colorectal), where it may promote tumor progression by enhancing angiogenesis, inhibiting apoptosis, or modulating immune evasion.
STC1 antibodies are essential tools for detecting and quantifying STC1 protein levels in research settings, enabling studies on its biological functions and pathological roles. These antibodies are utilized in techniques like immunohistochemistry, Western blotting, and ELISA to explore STC1’s expression patterns in normal versus diseased tissues. Recent studies suggest STC1 as a potential biomarker for cancer prognosis or a therapeutic target, given its association with aggressive tumor behavior and treatment resistance. However, its dual roles in cytoprotection and disease progression underscore the complexity of its regulatory mechanisms, necessitating further research. The development and validation of high-specificity STC1 antibodies remain critical for advancing both basic science and clinical applications.
×
